Novo Nordisk + OpenAI Deal

Novo Nordisk said on April 14 it is partnering with OpenAI to use artificial intelligence across drug research, manufacturing and commercial operations. (biospace.com) The Danish drugmaker said the tools will sift through large research datasets, flag possible drug candidates and shorten the path from lab work to patient use. Pilot programs start in research and development, manufacturing and commercial teams, with full integration planned by the end of 2026. (reuters.com) Drug discovery often starts with scanning huge volumes of biology and chemistry data for patterns that might point to a useful molecule. Novo said OpenAI’s systems will also be used in supply chains, distribution and corporate operations, not just in the lab. (cnbc.com) The deal lands as Novo tries to defend its position in obesity and diabetes medicines, where Wegovy and Ozempic made it one of Europe’s most valuable companies. Reuters reported that Eli Lilly won United States approval this month for its weight-loss pill Foundayo, adding pressure in the race for new treatments. (reuters.com) Novo did not disclose financial terms. Chief executive Mike Doustdar told Reuters the goal is “not replacing our scientists” but raising productivity and slowing the pace of future hiring, while OpenAI also helps train Novo’s workforce in artificial intelligence tools. (reuters.com) Drugmakers have been using artificial intelligence first on repetitive tasks such as finding clinical-trial sites, screening patients and preparing regulatory paperwork. CNBC cited consultant Ben van der Schaaf saying the industry is still not using artificial intelligence as an end-to-end system for discovering new medicines. (cnbc.com) Novo is adding OpenAI to a broader artificial intelligence push that already included a 2025 collaboration with Nvidia and Denmark’s Gefion sovereign artificial intelligence supercomputer. CNBC reported that effort focused on custom models and agents for early research and clinical development. (cnbc.com) Industry publication Pharmaceutical Technology said OpenAI has also signed healthcare deals with Sanofi, Moderna, Thermo Fisher Scientific and Eli Lilly, as drug companies look for faster ways to move from data to decisions. Novo’s bet is that the same software can speed both molecule hunting and the factory-and-distribution work that gets medicines to market. (pharmaceutical-technology.com)